Serum tumor marker CA 125 is an early and sensitive indicator of veno-occlusive disease in children undergoing bone marrow transplantation

Veno-occlusive disease (VOD) is a potentially lethal complication of patien ts undergoing bone marrow transplantation (BMT). The diagnosis of VOD is cu rrently based on clinical signs and unspecific laboratory findings. CA 125 is an oncofetal antigen used as a tumor marker in various malignancies, esp ecially in those originating from the female reproductive tract or gastroin testinal organs, whereas serum CA 125 levels are not increased in hematolog ical malignancies, Several pathophysiological alterations occurring in VOD may lead to elevations in serum CA 125 levels, Therefore, we explored the b ehavior of this marker as a diagnostic tool in VOD, Twenty-nine pediatric t ransplant patients were studied. Eight patients (28%) developed clinical VO D, and a significant increase in serum CA 125 was noted in all of them. Dur ing the 7 days preceding the diagnosis of VOD, an increase of at least 57% in serum CA 125 from the pre-BMT value was observed in 6 (86%) of 7 of the evaluable patients with VOD, In contrast, a similar increase was noted in o nly 6 of the 21 non-VOD patients during the post-BRIT period of 30 days. Ac cordingly, the sensitivity and specificity of serum CA 125 for predicting o r detecting VOD,were 86% and 71%, respectively. The serum levels of CA 125 were not affected by the presence of Graft-versus-Host Disease (GVHD) or a septic infection, In conclusion, serum CA 125 is of value as an early marke r of VOD in children undergoing BRIT.